Fruquintinib is a Small Molecule owned by Hutchison MediPharma, and is involved in 59 clinical trials, of which 17 were completed, 27 are ongoing, and 15 are planned.
Fruquintinib is an anti cancer agent. Fruquintinib is a selective, small molecule tyrosine kinase inhibitor of VEGF receptors 1, 2 and 3. The vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFRs) play a pivotal role in tumor-related angiogenesis. Inhibition of VEGF signaling in tumor vasculature represents an exciting therapeutic strategy, with the potential to arrest the development of new blood vessels essential for tumor growth and metastasis.
The revenue for Fruquintinib is expected to reach a total of $6.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Fruquintinib NPV Report.
Fruquintinib (Elunate) is an anti-neoplastic agent. It is formulated as hard gelatin capsules for oral route of administration. Elunate is indicated for the treatment of metastatic colorectal cancer patients, who have failed at least two prior systemic antineoplastic therapies including fluoropyrimidine, oxaliplatin and irinotecan, with or without prior use of anti-vascular endothelial growth factor or anti-epidermal growth factor receptor therapies.
Fruquintinib (HMPL-013) is under development for the treatment of locally advanced rectal cancer, desmoplastic small round cell tumor, epithelioid hemangioendothelioma, solitary fibroma, angiosarcoma, soft tissue sarcoma, advanced or metastatic triple negative breast cancer, HER2 negative breast cancer, metastatic colorectal adenocarcinoma, metastatic renal cell carcinoma, metastatic biliary tract adenocarcinoma, advanced solid tumor including gastric cancer, gastroesophageal junction adenocarcinoma and advanced non squamous non small cell lung cancer, ovarian cancer, endometrial cancer, cervical cancer, breast cancer, advanced or recurrent/metastatic pancreatic adenocarcinoma and meningioma. It is administered orally. It was also under development for hepatocellular carcinoma and thymic cancer.
Hutchmed China Overview
Hutchmed China (Hutchmed) formerly known as Hutchison China MediTech is a biopharmaceutical company which discovers, develops, manufactures and commercializes drugs for the treatment of solid tumors and hematological malignancies; and immunological disorders. It also offers over-the-counter (OTC) pharmaceuticals and consumer healthcare products. Hutchmed also provides R&D services to other companies. It has a broad pipeline of drug candidates indicated for the treatment of immunological diseases, besides novel oral drug candidates for various cancers and inflammation. It operates in China, North America, Europe and Australia. The company offers prescription drugs to hospitals in China through direct sales force. It distributes consumer health products in China. Hutchmed is headquartered in Kowloon, Hong Kong.
The company reported revenues of (US Dollars) US$356.1 million for the fiscal year ended December 2021 (FY2021), an increase of 56.2% over FY2020. The operating loss of the company was US$207 million in FY2021, compared to an operating loss of US$196.7 million in FY2020. The net loss of the company was US$194.7 million in FY2021, compared to a net loss of US$125.7 million in FY2020.
Quick View – Fruquintinib
|Highest Development Stage|